INOVIO VOCERYQ FDA Approval: Launch Plan, Competition and the Commercial Risks of Accelerated Approval
The INOVIO VOCERYQ FDA approval starts a launch in about 60 days. Competition, accelerated-approval risk and undisclosed price.
Read More
India Pharmaceutical Market Growth 2026: Who Is Capturing the 12% Rise to ₹70,180 Crore
Who captures India pharmaceutical market growth 2026? Sun, Torrent and Mankind outgrew the 12% market. Pricing and caveats.
Bristol Myers Squibb Q3 2026 Results: Growth Portfolio Now 59% of Sales as Eliquis Cliff Nears
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as the Growth Portfolio hits 59% of sales. The Eliquis cliff explained.
Laurus Labs Galenvs Acquisition: A Small Ticket Aimed at Oligonucleotide Capability
The Laurus Labs Galenvs acquisition is a US$3.75 million option on oligonucleotide skills. Deal math, strategy and risks.
Fortis Healthcare Acquisition: What ₹277 Crore for Suguna Hospital Says About Bengaluru Cluster Strategy
The Fortis Healthcare acquisition of Suguna Hospital: price per bed, the cluster strategy and the profit data not yet disclosed.
Ro Robin AI Health Agent: The Business Case for Keeping Patient Care In-House
The Ro Robin AI health agent fits a strategy of keeping more care in-house. The business logic, regulatory exposure and open questions.
Laurus Labs Q2 Results: How CDMO Mix Drove a 126% Jump in Net Profit
The Laurus Labs Q2 results show strong operating leverage from CDMO mix. Segment split, margin bridge and what is undisclosed.
BPaL TB Regimen Patent India: What the Rejection Means for Generic Makers and Procurement
The BPaL TB regimen patent India ruling may open the door to generics. What still stands in the way and who is affected.
FDA Medline Bed Alert: What the Market Exit Means for Hospitals and Care Homes
What the FDA Medline bed alert and Medline’s market exit mean for hospitals, care homes and procurement teams.